Temporal trends and current use of de-novo belatacept in kidney transplant recipients in the United StatesTemporal trends and current use of de-novo belatacept in kidney transplant recipients in the United States
|
| 0 Comment
The adoption of de-novo belatacept in kidney transplant (kTx) recipients was hampered by an elevated danger of acute mobile rejection (ACR) with variation in adopted belatacept primarily based immunosuppressive therapies